SEC Form 4 · accession 0001104659-19-010801
SUPERNUS PHARMACEUTICALS, INC. · SUPN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Stefan K.F. Schwabe
Officer — Executive Vice President R&D
Period of report
Feb 22, 2019
Accepted (ET)
Feb 26, 2019 · 7:28 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001356576
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | holding | — | — | — | 2,314 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F2 | $36.75 | Feb 22, 2019 | A | 40,000 | A | — | Feb 22, 2029 | Common Stock | 40,000 | 40,000 | D |
Explanation of responses
- F1Includes an aggregate of 347 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan subsequent to the date of the Reporting Person's most recent filing on Form 4.
- F2The option vests in four equal annual installments beginning on February 22, 2020.